Abstract
In their article, [Helwa et al. (2017)][1] show the effect of monomethylfumarate (MMF) in the treatment of psoriasis through enhancing the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and aquaporin-3 (AQP3). In our opinion, however, there are some doubts about the results of
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of pharmacology and experimental therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
